Big Pharma Split Corp Class A - Asset Resilience Ratio
Big Pharma Split Corp Class A (PRM) has an Asset Resilience Ratio of 89.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Big Pharma Split Corp Class A's Asset Resilience Ratio has changed over time. Check Big Pharma Split Corp Class A strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Big Pharma Split Corp Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRM market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$23.10 Million | 89.67% |
| Total Liquid Assets | CA$23.10 Million | 89.67% |
Asset Resilience Insights
- Very High Liquidity: Big Pharma Split Corp Class A maintains exceptional liquid asset reserves at 89.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Big Pharma Split Corp Class A Industry Peers by Asset Resilience Ratio
Compare Big Pharma Split Corp Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pearl Diver Credit Company Inc.
NYSE:PDCC |
Asset Management | 1.77% |
|
A.F.P. Provida
SN:PROVIDA |
Asset Management | 5.53% |
|
A.F.P. Habitat
SN:HABITAT |
Asset Management | 7.59% |
|
Hainan Haide Industry Co Ltd
SHE:000567 |
Asset Management | 32.29% |
|
Australian United Investment Company Ltd
AU:AUI |
Asset Management | 0.01% |
|
Trinity Capital Inc
NASDAQ:TRIN |
Asset Management | 3.31% |
|
PM Capital Global Opportunities Fund Ltd
AU:PGF |
Asset Management | 97.40% |
|
Magellan Financial Group Ltd
AU:MFG |
Asset Management | 15.56% |
Annual Asset Resilience Ratio for Big Pharma Split Corp Class A (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Big Pharma Split Corp Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 95.71% | CA$25.17 Million ≈ $18.21 Million |
CA$26.30 Million ≈ $19.03 Million |
+93.01pp |
| 2023-12-31 | 2.71% | CA$718.24K ≈ $519.56K |
CA$26.53 Million ≈ $19.19 Million |
-57.98pp |
| 2022-12-31 | 60.69% | CA$23.73 Million ≈ $17.16 Million |
CA$39.10 Million ≈ $28.28 Million |
-32.71pp |
| 2021-12-31 | 93.40% | CA$35.32 Million ≈ $25.55 Million |
CA$37.81 Million ≈ $27.35 Million |
-4.29pp |
| 2020-12-31 | 97.69% | CA$22.40 Million ≈ $16.21 Million |
CA$22.93 Million ≈ $16.59 Million |
+0.80pp |
| 2019-12-31 | 96.89% | CA$26.33 Million ≈ $19.05 Million |
CA$27.18 Million ≈ $19.66 Million |
-1.66pp |
| 2018-12-31 | 98.55% | CA$33.14 Million ≈ $23.98 Million |
CA$33.63 Million ≈ $24.33 Million |
+5.66pp |
| 2017-12-31 | 92.89% | CA$30.18 Million ≈ $21.83 Million |
CA$32.49 Million ≈ $23.50 Million |
-- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.